This interview contains forward-looking statements, including statements regarding the proposed acquisitions, expected closing timelines, anticipated financial contributions and accretion, and planned regulatory filings. These statements…
September 03, 2025
Advancing COYA 302 for ALS with Patient-Centered Vision
May 22, 2025
MetaVia Therapeutics: DA-1726 Advances as a Promising Contender in the Competitive Obesity Drug Landscape
April 15, 2025
Opus Genetics: Advancing Gene Therapy and Ophthalmic Innovation with Major Milestones Ahead
Forward-Looking Statements This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not…
March 21, 2025
NextNRG Delivers Record Growth Amid Surging Energy Demand and AI-Driven Infrastructure Investments
January 07, 2025
Quoin Pharmaceuticals Reveals Highly Positive Interim Data in Most Advanced and Comprehensive Netherton Syndrome Clinical Trials Under Open IND
December 18, 2024
Cardiol Therapeutics (Nasdaq: CRDL) Accelerates Late-Stage Trial Targeting $1B Recurrent Pericarditis Market, Aiming to Transform Heart Disease Care
Klotho Neurosciences, Inc. is a publicly listed biopharmaceutical company (Nasdaq: KLTO)
